Combos, New MOAs, And Oral Formulations Of Injectables: Lilly’s Immunology Strategy

 
• By David Wild

In a competitive immunology landscape, Eli Lilly is looking for novel agents, oral formulations of injectables, and combination therapies that can optimize response and expand the patient pool.

(Shutterstock)

More from Market Intelligence

More from Business Strategy